8-K: CNBX Pharmaceuticals Secures $55,000 Convertible Note with Potential for Additional $850,000 Investment

CNBX Pharmaceuticals entered into a convertible promissory note agreement for an immediate $55,000 and potential additional funding up to $850,000.

Summary

• CNBX Pharmaceuticals Inc. executed a 9-month Convertible Promissory Note on January 24, 2025, with an institutional investor.
• The agreement provides an immediate $55,000 to the company.
• Up to $850,000 may be tendered over the term of the note, subject to certain conditions.
• The note has a 9% Original Issue Discount (OID) and carries a 10% per annum interest rate.
• CNBX Pharmaceuticals has the right to redeem the note at 125% of its face value.
• The investor is prohibited from short-selling or hedging CNBX's common stock during the agreement's term.
• The company is obligated to register all shares that the investor may acquire.
• The holder has the right to convert the note into common stock starting 180 days after the issue date and ending on the maturity date (October 30, 2025) or the date of payment of the Default Amount.
• The conversion price is 65% of the Market Price, representing a 35% discount.
• The holder cannot convert any portion of the note that would result in beneficial ownership of more than 4.99% of the outstanding shares of Common Stock.
• The company must reserve four times the number of shares that is actually issuable upon full conversion of the Note.
• If the company fails to deliver common stock upon conversion by the deadline, it will pay the holder $2,000 per day in cash.
• The borrower has the right to prepay the outstanding note (principal and accrued interest), in full, with a prepayment percentage ranging from 110% to 130% depending on the period.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The company secures funding, but the terms of the convertible note include OID and potential dilution.

Positives

• CNBX Pharmaceuticals gains immediate access to $55,000 in funding.
• The potential for an additional $850,000 investment provides further financial flexibility.
• The company retains the right to redeem the note, offering control over its debt.
• The investor's agreement not to engage in short-selling or hedging may help stabilize the company's stock price.
• The borrower has the right to prepay the outstanding note (principal and accrued interest), in full, with a prepayment percentage ranging from 110% to 130% depending on the period.

Negatives

• The 9% OID reduces the actual amount received by the company upfront.
• The 10% annual interest rate increases the cost of borrowing.
• The conversion of the note could dilute existing shareholders' equity.
• The company's obligation to register the investor's shares adds administrative burden and potential costs.
• The borrower has the right to prepay the outstanding note (principal and accrued interest), in full, with a prepayment percentage ranging from 110% to 130% depending on the period.

Risks

• Failure to meet the obligations of the note could trigger events of default, leading to accelerated payment requirements and penalties.
• The conversion of the note could significantly dilute existing shareholders' equity, especially if the stock price declines.
• The company's ability to access the full $850,000 is subject to certain conditions, which may not be met.
• The company's obligation to register the investor's shares adds administrative burden and potential costs.
• The borrower has the right to prepay the outstanding note (principal and accrued interest), in full, with a prepayment percentage ranging from 110% to 130% depending on the period.

Future Outlook

The company anticipates utilizing the funds for general corporate purposes. The availability of the additional $850,000 is contingent upon meeting certain conditions.

Industry Context

Small biotech companies often use convertible notes to raise capital quickly, especially when access to traditional financing is limited. This type of financing can be attractive to investors seeking potential upside through equity conversion, but it also carries risks of dilution for existing shareholders.

Comparison to Industry Standards

• Convertible notes are a common financing tool for small-cap companies, particularly in the biotech and pharmaceutical sectors.
• The terms of this note, including the OID, interest rate, and conversion discount, are within the typical range for such agreements, but should be compared to similar deals involving companies with comparable risk profiles.
• Comparable companies that have used convertible notes include XOMA Corporation and Aeterna Zentaris Inc., although the specific terms of their notes may vary based on market conditions and company-specific factors.

Stakeholder Impact

• Shareholders may experience dilution if the note is converted into common stock.
• The funding provides CNBX Pharmaceuticals with additional capital to support its operations.
• Creditors may be impacted by the new debt obligation.
• Employees may benefit from the company's improved financial stability.

Next Steps

• CNBX Pharmaceuticals will receive the initial $55,000 in funding.
• The company will need to manage its obligations under the note, including interest payments and potential share registration.
• The company may seek to meet the conditions necessary to access the additional $850,000 in funding.
• The company will need to monitor its stock price and potential dilution from the note's conversion.

Key Dates